This week in drug discovery (7-11 August)  

News round-up for by DDW Digital Content Editor Diana Spencer.

The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients. Traditionally successful in treating blood cancers, it is positive to see companies pursuing CAR-T as an option for solid tumours, a potential new market for these treatments.

The top stories:

BlueRock and sign Treg therapies discovery deal

Bayer subsidiary BlueRock Therapeutics and have announced a collaboration to discover and manufacture regulatory T cell (Treg) based therapies.

Research partners advance AAV gene therapy for heart disease

Evox Therapeutics has agreed a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY, US.

Astellas invests in CAR-T cell therapy for solid tumours

Astellas Pharma will invest $50 million into Poseida Therapeutics to secure the rights to the company’s cancer CAR-T cell therapy for solid tumours, which is currently in Phase I trials.

Biologic CAR-T cell engager approved for UK clinical trial

The UK MHRA has granted Aleta Biotherapeutics a clinical trial authorisation to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR-T cell therapy.

Collaborators agree deal to develop CAR-T therapy for solid tumours

GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration to develop T-MAXIMUM’s CAR-T cell therapy using GenScript’s CRISPR nucleic acid reagents.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free